BioView Unveils Breakthrough Liquid Biopsy for HER2 Detection in Metastatic Breast Cancer
BioView’s liquid biopsy test offers a non-invasive method to detect HER2 status in metastatic breast cancer patients.
Category: Breast
Breast
Latest
Breast
Latest
The Breast Cancer Index Test is Guiding Hormone Therapy Decisions
BCI testing is reshaping treatment decisions for early-stage HR+ breast cancer patients by helping guide endocrine therapy choices.
Breast
Latest
Exai Bio’s RNA-Based Liquid Biopsy Platform Detects Early Stage Breast Cancer Accurately
Exai Bio's liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
How a Computational Model Predicts Genetic Risk for Breast Cancer
This computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read More
Breast Cancer Overdiagnosis Common Among Older Women
New findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read More
Devyser Debuts 2 Genetic Test Kits for Hereditary Cancer
Devyser LynchFAP and Devyser BRCA PALB2 genetic test kits offer efficient, targeted analysis of genes associated with increased cancer risk.
Read More
Exai Bio Expands RNA-based Breast Cancer Liquid Biopsy Platform through Collaboration
Exai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Read More
DCIS Risk Assessment Test Gets CMS Advanced Diagnostic Laboratory Test Status Approval
The Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for PreludeDx’s DCISionRT test.
Read More
Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer
Natera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read More
PreciseDx AI-Enabled Breast Diagnostic Gets Approval from NY State
PreciseDx announced that the NYSDOH approved the PDxBr, an LDT designed to enrich breast cancer grading and improve risk categorization.
Read More
AstraZeneca, Ibex Collaborate on Novel AI-Powered HER2 Scoring Product
The companies are collaborating on a product to aid pathologists with an accurate assessment of HER2 IHC scoring in breast cancer patients.Â
Read More
FDA Approves Guardant Health’s CDx Liquid Biopsy for Breast Cancer Patients
The FDA approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for metastatic breast cancer patients with ESR1 mutations.
Read More
Scientists Find New Marker that Predicts Early Breast Cancer Recurrence
Scientists found a marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
Read More
PreciseDx AI Platform Predicts Early-Stage Breast Cancer Recurrence
PreciseDx detailed its digital AI platform, which designed to enrich breast cancer grading and improve risk categorization.
Read More
Immune System B-cells Can Help Predict HER2-Positive Breast Cancer Treatment Response
Measuring activation of immune-system B cells may be an ideal method in predicting whether HER2-positive breast cancer responds to treatment.
Read More
Genetic Profiling May Identify Breast Cancer Patients Who Can Omit Radiation Therapy
Breast cancer patients who undergo breast-conserving surgery are recommended to do adjuvant radiation therapy to reduce local recurrence risk.
Read More
RNA-Based Liquid Biopsy Platform Detects Early-Stage Breast Cancer
Researchers released data demonstrating that an RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages.
Read More
Breast Cancer Index Test Predicts Treatment Benefit
Hologic, Inc. has released new study data showing that the Breast Cancer Index test identified which patients benefited from therapy.
Read More